All In Biotech

Drug Trial Radar · NCT07544862

A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

A Prospective Study of Stapokibart Injection in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jun 2, 2026

Primary completion

Dec 2027

Study completion Feb 2028

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • StapokibartBiological

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence rate of adverse reactionsTime frame: From enrollment to the end of treatment at 52 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.